Myriad Genetics Profit Margin

The latest profit margin for MYGN is -13.96% as of June 2026. That compares with -47.45% in the prior-year period — up 70.6% year over year. That is below the Healthcare sector average of 14.34%. Investors often review this figure alongside Myriad Genetics's historical trend and sector peers before judging valuation or financial health.

Over the past year, MYGN's profit margin moved from -47.45% to -13.96% — a 70.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Myriad Genetics's valuation or profitability profile.

Against Healthcare companies, MYGN currently prints -13.96% for profit margin, while the sector average sits near 14.34%. That is roughly 197.3% below the sector mean. Large gaps often invite a closer look at Myriad Genetics's growth, margins, and balance sheet.

Profit Margin shows how effectively Myriad Genetics converts resources into returns. At -13.96%, MYGN may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -47.45% in the prior-year period — up 70.6% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting MYGN's profit margin (-13.96%), review year-over-year change from -47.45%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.